How a lack of analogues could have undervalued a promising in-licensing opportunity
High unmet need offered a promising environment for a new asset; however, with no obvious analogues to quantify price potential, an approach ideal for an indication with no current treatments was needed…
Back to Case Studies
A great opportunity for a new asset, in an indication with no current therapies...
A top 20 pharma company wanted to evaluate the commercial potential of an in-licensing opportunity. This was for an infectious disease indication with no approved therapies available at the time.
A high level of unmet need presented a great commercial opportunity.
...But a lack of analogues made it difficult to identify an optimal price
The pharma company needed an accurate price evaluation to feed into the commercial decision and aid their negotiation strategy.
Often, to evaluate the price potential of in-licensing opportunities, analogues are used. However, with no available treatments on the market and very short timelines, quantifying the price potential of the asset would be difficult!
Interviews with payers were a potential solution, however this came with its own challenges…
